Pfizer Launches Process To Identify Chief Scientific Officer Successor
Pfizer Launches Process To Identify Chief Scientific Officer Successor
Pfizer, Inc. (NYSE:PFE) announced it is starting the process to find a new chief scientific officer and president of Pfizer Research and Development.
輝瑞公司（紐交所PFE）宣佈啓動尋找新首席科學官兼輝瑞研究與開發總裁的流程。
The Details: Mikael Dolsten, the current Chief Scientific Officer and President, is set to leave the company after 15 years. Dolsten will stay in his current role until a new chief scientific officer is hired.
詳情：現任首席科學官兼總裁Mikael Dolsten將在15年後離開公司。在新首席科學官被聘用之前，Dolsten將繼續擔任現在的角色。
Pfizer obtained more than 35 drug and vaccine approvals during Dolsten's tenure for products related to therapies for inflammatory diseases, cardiovascular, stroke prevention, hemophilia and cancer.
在Dolsten任職期間，輝瑞公司獲得了超過35種藥品和生物-疫苗的批准，主要用於治療炎症性疾病、心血管系統、中風預防、血友病和癌症方面。
"I am incredibly proud of all that we have accomplished in creating a world-class R&D organization with amazing talent, industry-leading scientific platforms, and a first-in-class pipeline and portfolio," said Dolsten.
Dolsten表示：“我爲我們所取得的成就感到非常自豪，我們創造了一個世界一流的研發組織，擁有行業領先的科學平台和一流的管道和產品組合。”
The process of finding Dolsten's replacement is anticipated to last several months. Separately, on July 1, the company announced the election of Cyrus Taraporevala to its Board of Directors and Audit Committee and Compensation Committee.
尋找Dolsten替代人選的流程預計需要數個月時間。另外，在7月1日，該公司宣佈將Cyrus Taraporevala選爲其董事會、審計委員會和薪酬委員會成員。
PFE Price Action: At the time of publication, Pfizer shares are trading 0.73% lower at $27.73 per data from Benzinga Pro.
PFE價格行動：根據Benzinga Pro的數據，在發佈時，輝瑞公司股票以每股27.73美元的價格下跌了0.73%。
Image: Photo via Shutterstock
圖像：通過shutterstock拍攝
譯文內容由第三人軟體翻譯。